Daratumumab and Recombinant Human Hyaluronidase
Sponsors
National Cancer Institute (NCI), Roswell Park Cancer Institute, Eden Biltibo, Alliance for Clinical Trials in Oncology
Conditions
Multiple MyelomaMultiple Myeloma (MM)Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Phase 1
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
RecruitingNCT06622005
Start: 2025-04-10End: 2030-04-10Target: 15Updated: 2026-08-13
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
WithdrawnNCT07082270
Start: 2026-04-01End: 2028-02-01Updated: 2026-05-15
Phase 2
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Active, not recruitingNCT06169215
Start: 2024-07-23End: 2027-09-23Updated: 2026-09-25
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RecruitingNCT06948084
Start: 2027-05-22End: 2028-02-28Target: 80Updated: 2026-10-28
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
RecruitingNCT07485647
Start: 2026-04-20End: 2029-04-01Target: 50Updated: 2026-08-19
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
RecruitingNCT07605416
Start: 2027-04-20End: 2032-11-06Target: 74Updated: 2026-10-26
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Not yet recruitingNCT07887984
Start: 2026-12-23End: 2053-08-01Target: 920Updated: 2026-10-22